Apilimod (STA-5326) is a drug that was initially identified as an inhibitor of production of the interleukins IL-12 and IL-23, and developed for the oral treatment of autoimmune conditions …

Mar 30, 2017 · Apilimod induces B-NHL cytotoxicity through a unique mechanism of action that involves the disruption of lysosomal function. We identified apilimod as an antiproliferative …

Apilimod is a potent and highly selective PIKfyve inhibitor. ChEBI APILIMOD is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational …

Apilimod, an inhibitor of PIKfyve, interferes with the endo/lysosomal trafficking and can indirectly block the activation of proteases as shown for Cathepsin B and L. Apilimod thereby likely …

Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, …

Apilimod is a potent small molecular inhibitor of IL-12/23 with an unknown target and has been evaluated in clinical trials for patients with Crohn’s disease or rheumatoid arthritis. Using a …

Dec 27, 2020 · The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell …

Apilimod is a small molecule that inhibits IL-12 and IL-23 production - cytokines that are involved in autoimmune diseases - through the prevention of nuclear translocation of c-Rel. Synta …

Nov 18, 2007 · Dual specificity kinase implicated in myriad essential cellular processes such as maintenance of endomembrane homeostasis, and endocytic-vacuolar pathway, lysosomal …

May 24, 2022 · In this study, we aim to evaluate the antiviral activity of XMU-MP-7 against SARS-CoV-2 and its various variants, especially the highly contagious Delta and the heaviest …